• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

ESBATech

edit

Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.

Recent Milestones

edit

• 
  ESBATech was acquired by Alcon. (9/13/09)
  Posted 9/22/09 at 7:30am via alconinc.com
• 
  ESBATech received $22M in Series B funding. (8/7/08)
  Posted 6/24/09 at 12:46am via fiercebiotech.com
• 
  ESBATech received $41M in Series B funding. (8/2/06)
  Posted 4/19/10 at 7:51pm via esbatech.com
• 
  ESBATech added Dominik Escher as Chief Executive Officer.
  Posted 6/24/09 at 12:36am
• 
  ESBATech added Martin Gertsch as Chief Financial Officer.
  Posted 6/24/09 at 12:36am

Videos

Screenshots

edit

Above: ESBATech
Uploaded: 6/24/09

Sources

1. Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG (invest.alconinc.com) [edit]
2. ESBATech Closes USD 41M Series B Venture Financing (esbatech.com) [edit]
3. ESBATech rounds up $22M in second round (fiercebiotech.com) [edit]